CA2700893A1 - Substituted tetrazole compounds and uses thereof - Google Patents

Substituted tetrazole compounds and uses thereof Download PDF

Info

Publication number
CA2700893A1
CA2700893A1 CA2700893A CA2700893A CA2700893A1 CA 2700893 A1 CA2700893 A1 CA 2700893A1 CA 2700893 A CA2700893 A CA 2700893A CA 2700893 A CA2700893 A CA 2700893A CA 2700893 A1 CA2700893 A1 CA 2700893A1
Authority
CA
Canada
Prior art keywords
tetrazol
isopropyl
methoxy
diol
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2700893A
Other languages
English (en)
French (fr)
Inventor
Rui-Yang Yang
Syed M. Ali
Mark A. Ashwell
Eugene Kelleher
Rocio Palma
Neil Westlund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2700893A1 publication Critical patent/CA2700893A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2700893A 2007-10-12 2008-10-14 Substituted tetrazole compounds and uses thereof Abandoned CA2700893A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97960107P 2007-10-12 2007-10-12
US60/979,601 2007-10-12
PCT/US2008/079755 WO2009049305A2 (en) 2007-10-12 2008-10-14 5- (2-hydroxyphenyl) tetrazoles as hsp90 inhibitors against cancer

Publications (1)

Publication Number Publication Date
CA2700893A1 true CA2700893A1 (en) 2009-04-16

Family

ID=40473811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2700893A Abandoned CA2700893A1 (en) 2007-10-12 2008-10-14 Substituted tetrazole compounds and uses thereof

Country Status (7)

Country Link
US (1) US7932279B2 (https=)
EP (1) EP2217580B1 (https=)
JP (1) JP4792128B2 (https=)
CN (1) CN101821247A (https=)
AT (1) ATE538105T1 (https=)
CA (1) CA2700893A1 (https=)
WO (1) WO2009049305A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2014034868A1 (ja) 2012-08-31 2014-03-06 株式会社エーピーアイ コーポレーション ビアリール化合物の製造方法
JP5881837B2 (ja) 2012-09-26 2016-03-09 株式会社エーピーアイ コーポレーション テトラゾール化合物の脱保護方法
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
EP3909577A1 (en) * 2020-05-13 2021-11-17 Fundación Profesor Novoa Santos Ubiquitin-ligase inhibitors for the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1486057A (en) * 1975-06-09 1977-09-14 Ici Ltd Hydroxyphenyl tetrazoles and their use in the extraction of metals
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6975843B2 (en) 2000-12-21 2005-12-13 Telefonaktiebolaget L M Ericsson (Publ) Method and an arrangement relating to telecommunications systems
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
JPWO2003030937A1 (ja) * 2001-10-05 2005-01-20 小野薬品工業株式会社 ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
MXPA06004657A (es) * 2003-10-28 2006-06-27 Pharmacia Corp Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
JPWO2005063222A1 (ja) * 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
JP2005225787A (ja) 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
WO2006011052A1 (en) 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
AR050084A1 (es) 2004-07-27 2006-09-27 Novartis Ag Derivados de bencimidazolona como inhibidores de hsp90
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
WO2006055760A1 (en) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP2006306755A (ja) 2005-04-27 2006-11-09 Nippon Kayaku Co Ltd 新規なピラゾール誘導体とそれを有効成分とするｈｓｐ９０阻害剤
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
JP5178515B2 (ja) * 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
WO2007094819A2 (en) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP1951679B1 (en) * 2005-08-18 2015-02-18 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
EP2013218A2 (en) 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses

Also Published As

Publication number Publication date
US7932279B2 (en) 2011-04-26
US20090130117A1 (en) 2009-05-21
JP2011500603A (ja) 2011-01-06
CN101821247A (zh) 2010-09-01
WO2009049305A2 (en) 2009-04-16
JP4792128B2 (ja) 2011-10-12
EP2217580B1 (en) 2011-12-21
EP2217580A2 (en) 2010-08-18
WO2009049305A3 (en) 2009-07-02
ATE538105T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
KR102885432B1 (ko) CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물
JP6954567B2 (ja) ２−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
DE69719191T2 (de) Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
ES2308441T3 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos.
CA2753061C (en) Novel hetero pyrrole analogs acting on cannabinoid receptors
JP2008526887A (ja) カンナビノイド受容体に作用する新規なヘテロピロール類似体
SK8752003A3 (en) CXCR3 antagonists, pharmaceutical composition comprising same and use thereof
JP2017522346A (ja) ブロモドメインに対して活性な化合物
HUE027217T2 (en) Benzodioxinyl substituted indazole derivatives
US20100261710A1 (en) HDAC Inhibitors
CA2704282A1 (en) Quinazolinone compounds and methods of use thereof
CA2700893A1 (en) Substituted tetrazole compounds and uses thereof
CN116354901B (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
AU2012229859C1 (en) Nitrogen-containing saturated heterocyclic compound
KR102939061B1 (ko) 화합물 및 mif 억제제로서의 용도
CZ20023243A3 (cs) Pyrrolidinové deriváty, způsob jejich výroby, jejich pouľití a farmaceutický prostředek
JP2011500603A5 (https=)
JP2006117568A (ja) チオフェン環を有する新規アミド誘導体及びその医薬としての用途
CN106632076A (zh) 4,6‑二苯基嘧啶类化合物、其制备方法和医药用途
JP2008513443A (ja) 新規ヘテロ環式アミド
CN111491923B (zh) N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途
CN116348114A (zh) 硫代苯并咪唑衍生物或其药学上可接受的盐及其用途
JP3258531B2 (ja) ベンズイミダゾール誘導体
AU2023383986A1 (en) Novel bicyclic pd-l1 inhibitors, preparation methods therefor and medicinal uses thereof
WO2025064325A1 (en) Gpr35 modulators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130926